This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Postnatal care in gestational diabetes - including further glucose screening

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Women who have been diagnosed with gestational diabetes should discontinue blood glucose-lowering therapy immediately after birth - this will be done via specialist advice.

For women who were diagnosed with gestational diabetes and whose blood glucose levels returned to normal after the birth:

  • offer lifestyle advice (including weight control, diet and exercise)

  • offer a fasting plasma glucose test 6-13 weeks after the birth to exclude diabetes (for practical reasons this might take place at the 6-week postnatal check)

  • if a fasting plasma glucose test has not been performed by 13 weeks, offer a fasting plasma glucose test, or an HbA1c test if a fasting plasma glucose test is not possible, after 13 weeks

  • do not routinely offer a 75 g 2-hour OGTT

For women having a fasting plasma glucose test as the postnatal test:

  • women with a fasting plasma glucose level below 6.0 mmol/litre should be advised that:
    • have a low probability of having diabetes at present
    • should continue to follow the lifestyle advice (including weight control, diet and exercise) given after the birth
    • will need an annual test to check that their blood glucose levels are normal
    • have a moderate risk of developing type 2 diabetes
  • women with a fasting plasma glucose level between 6.0 and 6.9 mmol/litre should be advised that
    • are at high risk of developing type 2 diabetes, and offer them advice, guidance and interventions in line with the NICE guideline on preventing type 2 diabetes
  • women with a fasting plasma glucose level of 7.0 mmol/litre or above should be advised that
    • are likely to have type 2 diabetes, and offer them a diagnostic test to confirm diabetes

For women having an HbA1c test as the postnatal test:

  • women with an HbA1c level below 39 mmol/mol (5.7%) should be advised that:
    • have a low probability of having diabetes at present
    • should continue to follow the lifestyle advice (including weight control, diet and exercise) given after the birth
    • will need an annual test to check that their blood glucose levels are normal
    • have a moderate risk of developing type 2 diabetes, and offer them advice and guidance in line with the NICE guideline on preventing type 2 diabetes

  • women with an HbA1c level between 39 and 47 mmol/mol (5.7% and 6.4%) should be
    • advised that they are at high risk of developing type 2 diabetes, and offer them advice, guidance and interventions in line with the NICE guideline on preventing type 2 diabetes

  • women with an HbA1c level of 48 mmol/mol (6.5%) or above should be
    • advised that they have type 2 diabetes and refer them for further care

Offer an annual HbA1c test to women who were diagnosed with gestational diabetes who have a negative postnatal test for diabetes

Subsequent pregnancies:

  • women who were diagnosed with gestational diabetes should be offered early self-monitoring of blood glucose or an OGTT in future pregnancies
    • offer a subsequent OGTT if the first OGTT results in early pregnancy are normal

Breastfeeding and effects on glycaemic control

  • women with insulin-treated pre-existing diabetes should reduce their insulin immediately after birth and monitor their blood glucose levels carefully to establish the appropriate dose
  • women with insulin-treated pre-existing diabetes should be informed that they are at increased risk of hypoglycaemia in the postnatal period, especially when breastfeeding, and they should be advised to have a meal or snack available before or during feeds
  • women who have been diagnosed with gestational diabetes should discontinue hypoglycaemic treatment immediately after birth.
  • women with pre-existing type 2 diabetes who are breastfeeding can resume or continue to take metformin and glibenclamide immediately following birth but other oral hypoglycaemic agents should be avoided while breastfeeding

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.